China Lung Cancer Therapeutics Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

China accounts for a substantial share of the Asia Pacific lung cancer therapeutics market, driven by its large patient population and increasing healthcare expenditure. The market encompasses treatments for non-small cell lung cancer (NSCLC), which represents approximately 85% of all lung cancer cases, as well as small cell lung cancer and other rarer variants. Recent years have seen a shift from traditional chemotherapy toward precision medicine approaches, including tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors, and antibody-drug conjugates.

• •China represents the largest single-country market within Asia Pacific for lung cancer drugs, with NSCLC dominating the indication mix
• •The market has transitioned significantly from chemotherapy-centric treatment paradigms toward targeted therapies and immunotherapies since the late 2010s
• •Market valuation of approximately $12.0 billion in 2025 positions China as a primary growth engine for the broader Asia Pacific oncology sector

The primary driver of market expansion is the rising prevalence of lung cancer in China, linked to high smoking rates, environmental pollution, and demographic aging. China's aging population is expected to increase demand as cancer incidence rises sharply among individuals over 60 years old. Policy reforms have accelerated the approval process for innovative cancer drugs, with regulatory authorities implementing priority review pathways and conditional approvals for oncology products.

• •Rising incidence of lung cancer in China, with the country reporting over 800,000 new cases annually, making it the second-largest lung cancer burden globally
• •Regulatory reforms by China's National Medical Products Administration (NMPA) have significantly reduced drug approval timelines and expanded access to imported oncology therapies
• •Expanding insurance coverage through China's National Reimbursement Drug List (NRDL) has improved patient access to expensive targeted and immunotherapies

Within the market, non-small cell lung cancer dominates, with targeted therapies for EGFR, ALK, ROS1, and other genetic mutations representing the fastest-growing treatment category. Geographically, the eastern coastal provinces including Shanghai, Beijing, and Guangdong account for the largest share of market value, though demand is expanding rapidly in second and third-tier cities. Immunotherapy, particularly PD-L1 and PD-1 inhibitors, has emerged as a major growth segment alongside targeted therapies.

• •Targeted therapies for EGFR-mutated NSCLC constitute the largest molecularly-defined segment, reflecting the high prevalence of EGFR mutations in Chinese lung cancer patients
• •Immunotherapy products, particularly PD-1/PD-L1 inhibitors, have grown from virtually zero market share a decade ago to represent a multi-billion dollar segment
• •The hospital segment commands over 80% of treatment volume, with specialized cancer centers and general hospitals driving therapy adoption patterns

What are the recent trends and outlook?

The market is trending toward combination therapies and next-generation targeted agents, with an increasing number of clinical trials conducted in China rather than relying solely on global development programs. Biosimilar competition is expected to intensify as patent expiries approach for several blockbuster oncology drugs, potentially moderating pricing while expanding access. The long-term outlook projects sustained 13%+ annual growth through 2031, driven by pipeline innovation, continued NRDL expansion, and earlier-stage adoption of precision medicine.

• •China is increasingly becoming a first-in-class clinical trial destination, with multinational companies launching global Phase III trials from Chinese patient populations
• •ADC (antibody-drug conjugate) therapies represent the emerging frontier, with several products in late-stage development for EGFR-positive and HER2-positive lung cancer subtypes
• •Market growth of 13.6% CAGR is projected to continue through the early 2030s, potentially reaching approximately $28-30 billion by 2031